Design of potent GlyT1 inhibitors: In vitro and in vivo profiles

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 6, 2008, Pages 591-601

  Bridges, T M ^a   Williams, R ^a   Lindsley, C W ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Drug discovery; Glycine; GlyT1; Inhibitor; NMDA receptor; Schizophrenia

Indexed keywords

7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; ALX 5407; BENZOYLPIPERAZINE; CP 802079; DIZOCILPINE; FLUOXETINE; GLYCINE TRANSPORTER 1; GLYCINE TRANSPORTER 1 INHIBITOR; GLYCYLDODECYLAMIDE; INDAN 1,2 DIONE; LY 2365109; LY 637023; METHYLPHENIDATE; N (2 ARYLCYCLOHEXYL); N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; ORG 24461; ORG 24598; ORG 25935; PIPERAZINYL ACETIC ACID; SARCOSINE; SSR 103800; SSR 5047734; UNCLASSIFIED DRUG;

ATAXIA; DRUG DESIGN; DRUG INDUSTRY; DRUG RESEARCH; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RESPIRATORY FUNCTION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT;

ANIMALS; ANTIPSYCHOTIC AGENTS; DRUG DESIGN; GLYCINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MODELS, BIOLOGICAL; RECEPTORS, N-METHYL-D-ASPARTATE; SARCOSINE;

EID: 57349094379     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Lindsley CW, Wolkenberg SE, Kinney GG: Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors. Curr Topics Med Chem (2006) 6(17):1883-1896.
2. Sur C, Kiney GG: Glycine transporter 1 inhibitors and modulation of NMDA receptor-mediated excitatory neurotransmission. Current Drug Targets (2007) 8(5):643-649.
3. Andreasen NC: Schizophrenia: The fundamental questions. Brain Res Brain Res Rev (2000) 31(2-3):106-112.
4. Javitt DC, Zukin SR: Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry (1991) 148(10):1301-1308.
5. Millan MJ: N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: A critical review. Curr Drug Target CNS Neurol Disord (2002) 1(2):191-213.
6. Olney JW, Newcomer JW, Farber NB: NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res (1999) 33(6):523-533.
7. Aprison MH: The discovery of the neurotransmitter role of glycine. In: Glycine Neurotransmission. Ottersen OP, Storm-Mathisen J (Eds), John Wiley and Sons, Chichester, West Sussex, UK (1990):1-23.
8. Johnson JW, Ascher P: Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature (1987) 325(6104):529-531.
9. Betz H: Ligand-gated ion channels in the brain: The amino acid receptor superfamily. Neuron (1990) 5(4):383-392.
10. Danysz W, Parsons AC: Glycine and N-methyl-D- aspartate receptors: Physiological significance and possible therapeutic applications. Pharmacol Rev (1998) 50(4):597-664.
11. Paoletti P, Neyton J: NMDA receptor subunits: Function and pharmacology. Curr Opin Pharmacol (2007) 7(1):39-47.
12. Parsons CG, Danysz W, Hesselink M, Hartmann S, Lorenz B, Wollenburg C, Quack G: Modulation of NMDA receptors by glycine - introduction to some basic aspects and recent developments. Amino Acids (1998) 14(1-3):207-216.
13. Borowsky B, Mezey E, Hoffmann BJ: Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene. Neuron (1993) 10(5):851-863.
14. Kim KM, Kingsmore SF, Han H, Yang-Feng TL, Godinot N, Seldin MF, Caron MG, Giros B: Cloning of the human glycine transporter type 1: Molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene. Mol Pharmacol (1994) 45(4):608-617.
15. Liu QR, López-Corcuera B, Mandiyan S, Nelson H, Nelson N: Cloning and expression of a spinal cord- and brain-specific glycine transporter with novel structural features. J Biol Chem (1993) 268(30):22802-22808.
16. Morrow JA, Collie IT, Dunbar DR, Walker GB, Shahid M, Hill DR: Molecular cloning and functional expression of the human glycine transporter GlyT2 and chromosomal localization of the gene in the human genome. FEBS Lett (1998) 439(3):334-340.
17. Smith KE, Borden LA, Hartig PR, Branchek T, Weinshank RL: Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron (1992) 8(5):927-935.
18. Nelson N: The family of Na+/Cl- neurotransmitter transporters. J Neurochem (1998) 71(5):1785-1803.
19. Ebihara S, Yamamoto T, Obata K, Yanagawa Y: Gene structure and alternative splicing of the mouse glycine transporter type-2. Biochem Biophysical Res Comm (2004) 317(3):857-864.
20. Zafra F, Aragón C, Olivares L, Danbolt NC, Giménez C, Storm-Mathisen J: Glycine transporters are differentially expressed among CNS cells. J Neurosci (1995) 15(5 Pt 2):3952-3969.
21. Zafra F, Gomeza J, Olivares L, Aragón C, Giménez C: Regional distribution and developmental variation of the glycine transporters GlyT1 and GlyT2 in the rat CNS. Eur J Neurosci (1995) 7(6):1342-1352.
22. Cubelos B, Giménez C, Zafra F: Location of the GlyT1 glycine transporter at glutamatergic synapses in the rat brain. Cereb Cortex (2005) 15(4):448-459.
23. Tsai SJ, Cheng CY, Hong CJ, Liao DL, Hou SJ, Yen FC, Liou YJ: Association study of polymorphisms in glycine transporter with schizophrenia. J Neural Transm (2006) 113(10):1545-1549.
24. Henjum S, Hassel B: High affinity glycine and glutamate transport in pig forebrain white and gray matter: A quantitative study. Neurochem Int (2007) 50(5):696-702.
25. Szoke K, Härtel K, Grass D, Hirrlinger PG, Hirrlinger J, Hülsmann S: Glycine transporter 1 expression in the ventral respiratory group is restricted to protoplasmic astrocytes. Brain Res (2006) 1119(1):182-189.
26. Zhang LH, Gong N, Fei D, Xu L, Xu TL: Glycine uptake regulates hippocampal network activity via glycine receptor-mediated tonic inhibition. Neuropsychopharmacology (2008) 33(3):701-711.
27. Gomeza J, Hülsmann S, Ohno K, Eulenburg V, Szöke K, Richter D, Betz H: Inactivation of the glycine transporter 1 gene discloses a vital role of glial glycine uptake in glycinergic inhibition. Neuron (2003) 40(4):785-796.
28. Tsai G, Ralph-Williams RJ, Martina M, Bergeron R, Berger-Sweeney J, Dunham KS, Jiang Z, Caine SB, Coyle JT: Gene knockout of glycine transporter 1: Characterization of the behavioral phenotype. Proc Natl Acad Sci USA (2004) 101(22):8485-8490.
29. Burnet PW, Hutchinson L, von Hesling M, Gilbert EJ, Brandon NJ, Rutter AR, Hutson PH, Harrison PJ: Expression of D-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia. Schizophr Res (2008) 102(1-3):283-294.
30. Morita K, Motoyama N, Kitayama T, Morioka N, Kifune K, Dohi T: Spinal antiallodynia action of glycine transporter inhibitors in neuropathic pain models in mice. J Pharmacol Exp Ther (2008) 326(2):633-645.
31. Yee BK, Balic E, Singer P, Schwerdel C, Grampp T, Gabernet L, Knuesel I, Benke D, Feldon J, Mohler H, Boison D: Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile. J Neurosci (2006) 26(12):3169-3181.
32. Tsai G, Lane HY, Yang P, Chong MY, Lange N: Glycine transporter 1 inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry (2004) 55(5):452-456.
33. Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M: Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry (1999) 56(1):29-36.
34. Vandenberg RJ, Aubrey KR: Glycine transport inhibitors as potential antipsychotic drugs. Expert Opin Ther Targets (2001) 5(4):507-518.
35. Slassi A, Egle I: Recent progress in the use of glycine transporter-1 inhibitors for the treatment of central and peripheral nervous system diseases. Expert Opin Ther Patents (2004) 14(2):201-214.
36. Sur C, Kinney GG: The therapeutic potential of glycine transporter-1 inhibitors. Expert Opin Investig Drugs (2004) 13(5):515-521.
37. Lowe JA 3rd: Novel inhibitors of the type 1 transporter for glycine (GlyT1) as antipsychotic agents. Expert Opin Ther Patents (2005) 15(11):1657-1662.
38. Lechner SM: Glutamate-based therapeutic approaches: Inhibitors of glycine transport. Curr Opin Pharmacol (2006) 6(1):75-81.
39. Hashimoto K: Glycine transporter inhibitors as therapeutic agents for schizophrenia. Rec Pat CNS Drug Disc (2006) 1(1):43-53.
40. Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL Jr, Sur C, Kinney GG: Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr Topics Med Chem (2006) 6(8):771-785.
41. Atkinson BN, Bell SC, De Vivo M, Kowalski LR, Lechner SM, Ognyanov VI, Than CS, Tsai C, Jia J, Ashton D, Klitenick MA: ALX 5407: A potent, selective inhibitor of the hGlyT1 glycine transporter. Mol Pharmacol (2001) 60(6):1414-1420.
42. Aubrey KR, Vandenberg RJ: N-(3-[4′-fluorophenyl]-3- [4′-phenylphenoxy]propyl)sarcosine (NFPS) is a selective persistent inhibitor of glycine transport. Br J Pharmacol (2001) 134(7):1429-1436.
43. Berger AJ, Dieudonné S, Ascher P: Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J Neurophysiol (1998) 80(6):3336-3340.
44. Bergeron R, Meyer TM, Coyle JT, Greene RW: Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc Natl Acad Sci USA (1998) 95(26):15730-15734.
45. Chen L, Muhlhauser M, Yang CR: Glycine transporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J Neurophysiol (2003) 89(2):691-703.
46. Kinney GG, Sur C, Burno M, Mallorga PJ, Williams JB, Figueroa DJ, Wittman M, Lemaire W, Conn JP: The glycine transporter type 1 inhibitor N-[3-(4′-fluorophenyl)-3-(4'-phenylphenoxy)propyl] sarcosine potentiates NMDAR receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci (2003) 23(20):7586-7591. •• NFPS, a potent and selective GlyT1 inhibitor, provided early pharmacological and physiological characterization of GlyT1 within the context of the NMDAR hypofunction hypothesis of schizophrenia.
47. Javitt DC, Sershen H, Hashim A, Lajtha A: Reversal of phencyclidine-induced hyperactivity by glycine and the glycine uptake inhibitor glycyldodecylamide. Neuropsychopharmacology (1997) 17(3):202-204.
48. Toth E, Lajtha A: Antagonism of phencyclidine-induced hyperactivity by glycine in mice. Neurochem Res (1986) 11(3):393-400.
49. McCaughran J Jr, Mahjubi E, Decena E, Hitzemann R: Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition. Psychopharmacology (1997) 134(2):131-139.
50. Harsing LG Jr, Gacsalyi I, Szabo G, Schmidt E, Sziray N, Sebban C, Tesolin-Decros B, Matyus P, Egyed A, Spedding M, Levay G: The glycine transporter-1 inhibitors NFPS and Org 24461: A pharmacological study. Pharmacol Biochem Behav (2003) 74(4):811-825.
51. Le Pen G, Kew J, Alberati D, Borroni E, Heitz MP, Moreau JL: Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: Reversal by glycine and a glycine transport inhibitor. Biol Psychiatry (2003) 54(11):1162-1170.
52. Lipska BK, Weinerger DR: Delayed effects of neonatal hippocampal damage on haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. Brain Res Dev Brain Res (1993) 75(2):213-222.
53. 3H]-(R)-NPTS, a radioligand for the type 1 glycine transporter. Bioorg Med Chem Lett (2003) 13(7):1291-1292.
54. Martina M, Gorfinkel Y, Halman S, Lowe JA, Periyalwar P, Schmidt CJ, Bergeron R: Glycine transporter type 1 blockage changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J Physiol (2004) 557(2):489-500.
55. Thomson CG, Duncan K, Fletcher SR, Huscroft IT, Pillai G, Raubo P, Smith AJ, Stead D: Sarcosine based indandione hGlyT1 inhibitors. Bioorg Med Chem Lett (2006) 16(5):1388-1391.
56. Smith G, Ruhland T, Mikkelsen G, Andersen K, Christoffersen CT, Alifrangis LH, Mork A, Wren SP, Harris N, Wyman BM, Brandt G: The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as GlyT-1 inhibitors. Bioorg Med Chem Lett (2004) 14(15):4027-4030.
57. Walter MW, Hoffman BJ, Gordon K, Johnson K, Love P, Jones M, Man T, Phebus L, Reel JK, Rudyk HC, Shannon H et al: Discovery and SAR studies of novel GlyT1 inhibitors. Bioorg Med Chem Lett (2007) 17(18):5233-5238. • A new sarcosine-based GlyT1 inhibitor series comparable to NFPS for elevation of Gly in the CSF.
58. Perry KW, Falcone JF, Fell MJ, Ryder JW, Yu H, Love PL, Katner J, Gordon KD, Wade MR, Man T, Nomikos GG et al: Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology (2008) 55(5):743-754.
59. Papp A, Juranyi Z, Nagymajtenyi L, Matyus P, Harsing LG: The synaptic and nonsynaptic glycine transporter type-1 inhibitors Org-24461 and NFPS alter single neuron firing rate in the rat dorsal raphe nucleus. Neurochem Int (2008) 52(1-2):130-134.
60. Molander A, Lidö HH, Löf E, Ericson M, Söderpalm B: The glycine reuptake inhibitor Org 25935 decreases ethanol intake and preference in male Wistar rats. Alcohol Alcohol (2007) 42(1):11-18. •• GlyT1 inhibitors may have therapeutic relevance for treatment of alcohol dependence.
61. Molander A, Lof E, Stomberg R, Ericson M, Soderpalm B: Involvement of accumbal glycine receptors in the regulation of voluntary ethanol intake in the rat. Alcohol Clin Exp Res (2005) 29(1):38-45.
62. Gomeza J, Hülsmann S, Ohno K, Eulenburg V, Szöke K, Richter D, Betz H: Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition. Neuron (2003) 40(4):785-796.
63. Marino PJ, Conn PJ: Direct and indirect modulation of the N-methyl-D-aspartate receptor: Potential for the development of novel antipsychotic therapies. Curr Drug Targets - CNS & Neur Disord (2002) 1(1):1-16.
64. Kinney GG, Sur C: Glycine site modulators and glycine transporter-1 inhibitors as novel targets for therapeutic targets for the treatment of schizophrenia. Curr Neuropharmacol (2005) 3(1):35-43.
65. Pinard E, Ceccarelli SM, Stadler H, Alberati D: Discovery of N-(2-aryl-cyclohexyl) substituted spiropiperdines as a novel class of GlyT1 inhibitors. Bioorg Med Chem Lett (2006) 16(2):349- 353. • One of the first detailed descriptions of SAR and DMPK for a series of non-sarcosine-based GlyT1 inhibitors.
66. Ceccarelli SM, Pinard E, Stadler H, Alberati D: Discovery of N-(2-hydroxy-2-aryl-cyclohexyl) substituted spiropiperdines as GlyT1 antagonists with improved pharmacological profile. Bioorg Med Chem Lett (2006) 16(2):354-357.
67. Pinard E, Alberati D, Borroni E, Fischer G, Hainzl D, Jolidon S, Moreau JL, Narquizian R, Nettekoven M, Norcross RD, Stalder H, Thomas AW: Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors. Bioorg Med Chem Lett (2008) 18(18):5134-5139.
68. Depoortere R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, Poncelet M, Heaulme M, Santucci V, Decobert M, Cudennec A et al: Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new antipsychotic. Neuropsychopharmacology (2005) 30(11):1963- 1985. •• SSR-504734 substantiated the NMDAR hypofunction hypothesis of schizophrenia.
69. Singer P, Feldon J, Yee BK: The glycine transporter 1 inhibitor SSR504734 enhances working memory performance in a continuous delayed alternation task in C57BL/6 mice. Psychopharmacology (2008):doi:10.1007/s00213-008-1286-5.
70. Boulay D, Pichat P, Dargazanli G, Estenne-Bouhtou G, Terranova JP, Rogacki N, Stemmelin J, Coste A, Lanneau C, Desvignes C, Cohen C et al: Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacol Biochem Behav (2008) 91(1):47-58.
71. Black MD, Varty GB, Arad M, Barak S, De Levie A, Boulay D, Pichat P, Griebel G, Weiner I: Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: Latent inhibition studies in the rat. Psychopharmacology (Berl) (2008):doi:10.1007/s00213-008-1289-2.
72. Lindsley CW, Zhao Z, Leister WH, O'Brien J, Lemaire W, Williams DL Jr, Chen TB, Chang RS, Burno M, Jacobson MA, Sur C et al: Design, synthesis, and in vivo efficacy of glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-phenyl-1-(propylsulfonyl) piperidine-4-yl]methyl benzamides. ChemMedChem (2006) 1(8):807-811. •• Non-sarcosine-based GlyT1 inhibitor series from Merck that possessed favorable inhibitor profiles overall, but was subject to time-dependent TDI-related issues.
73. Zhao Z, O'Brien JA, Lemaire W, Williams DL Jr, Jacobson MA, Sur C, Pettibone DJ, Tiller PR, Smith S, Hartman GD, Wolkenberg SE et al: Synthesis and SAR of GlyT1 inhibitors derived from a series of N-((4-(morpholine-4-carbonyl)-1-(propylsulfonyl)piperidine-4-yl) -methyl)benzamides. Bioorg Med Chem Lett (2006) 16(23):5968- 5972. •• TDI-related issues of the parent series were alleviated, but P-gp inhibition susceptibility and compromised brain penetration were introduced.
74. Zeng Z, O'Brien JA, Lemaire W, O'Malley SS, Miller PJ, Zhao Z, Wallace MA, Raab C, Lindsley CW, Sur C, Williams DL Jr: A novel radioligand for glycine transporter 1: Characterization and use in autoradiographic and in vivo brain occupancy studies. Nucl Med Biol (2008) 35(5):315-325.
75. Lowe J, Drozda S, Qian W, Peakman MC, Liu J, Gibbs J, Harms J, Schmidt C, Fisher K, Strick C, Schmidt A et al: A novel, nonsubstrate-based series of glycine type 1 transporter inhibitors derived from high-throughput screening. Bioorg Med Chem Lett (2007) 17(6):1675-1678.
76. JANSSEN PHARMACEUTICA NV (Luyten HML, Janssens FE, Kennis LEJ): Glycine transport inhibitors. WO-199944596 (1999).
77. GLIATECH INC (Ali SM, Brunden KR, Jiang JB): Preparation of thioureas as glycine transport inhibitors. WO-00222581 (2002).
78. SMITHKLINE BEECHAM PLC (Coulton S, Hadley MS, Herdon HJ): GlyT1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders. WO-03055478 (2003).
79. GLAXO WELLCOME PLC (Branch CL, Nash DJ, Porter RA): GlyT1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders. WO-2004113280 (2004).
80. F HOFFMANN-LA ROCHE LTD (Alberti-Giani D, Jolidon S, Narquizian R, Nettekoven MH, Norcross RD, Pinard E, Stadler H): 1-Benzoylpiperazine derivatives as glycine uptake inhibitors for the treatment of psychoses. WO-2005023261 (2005).
81. F HOFFMANN-LA ROCHE AG (Ceccarelli S, Pinard E, Stadler H): Preparation of triaza-spiropiperidine derivatives for use as GlyT-1 inhibitors in the treatment of neurological and neuropsychiatric disorders. WO-2005040166 (2005).
82. 2C receptor antagonists. WO-2004089931 (2004).
83. 2C receptor antagonists. WO-2004089932 (2004).
84. NPS ALLELIX CORP (Egle IR, Frey J, Isaac MB, Slassi A, Begleiter LE, Edwards LG, Stefanac T, Tehim A, Maddaford SP, Tse HA): Aminopiperidines for use as GlyT1-inhibitors. WO-2001081308 (2001).
85. MERCK & CO INC (Lindsley CW, Wisnoski DD, Zhao Z): 4-phenyl -piperidine sulfonyl glycine transporter inhibitors. WO-2005046601 (2005).
86. MERCK & CO INC (Blackaby W, Duggan ME, Hallett D, Hartman GD, Jennings AS, Leister WH, Lewis RT, Lindsley CW, Naylor E, Street LJ, Wang Y et al): Heteroaryl piperidine glycine transporter inhibitors. WO-2005094514 (2005).
87. MERCK & CO INC (Lindsley CW, Hallet D, Wolkenberg SE): Azetidine glycine transporter inhibitors. WO-2005110983 (2005).
88. GLAXO WELLCOME PLC (Bradley DM, Branch CL, Marshall H, Nash DJ, Porter RA): Compounds. WO-2005058885 (2005).
89. GLAXO WELLCOME PLC (Bradley DM, Branch CL, Marshall H, Nash DJ, Porter RA): Compounds having morpholinyl and piperidinyl groups for use as GlyT1 and GlyT2 inhibitors. WO-2005058882 (2005).
90. GLAXO WELLCOME PLC (Bradley DM, Branch CL, Marshal H, Nash DJ, Porter RA): Glycine transporter-1 inhibitors. WO-2005058317 (2005).
91. SANOFI-AVENTIS (Dargazanli G, Estenne-Bouhtou G, Magat P, Marabout P, Roger P): Derivatives of N-[phenyl(pyrrolidine-2- yl)methyl]benzamide and N-[(azepan-2-yl)phenylmethyl] benzamide, preparation method thereof and application of same in therapeutics. WO-2005037785 (2005).
92. SANOFI-SYNTHÉLABO (Dachary E, Dargazanli G, Estenne-Bouhtou G, Veronique C): N-[phenyl(piperidin-2-yl)methyl] benzamide derivatives, preparation thereof, and use thereof in therapy. WO-2004013100 (2004).
93. SANOFI-SYNTHÉLABO (Dachary E, Dargazanli G, Estenne-Bouhtou G, Veronique C): N-[phenyl(piperidin-2-yl)methyl] benzamide derivatives, preparation thereof, and use thereof in therapy. WO-2004013101 (2004).
94. SANOFI-aVENTIS (Dargazanli G, Estenne-Bouhtou G, Veronique C): Derivatives of N-[phenyl(alkylpiperidine-2-yl) methyl] benzamide, preparation method thereof and application of same in therapeutics. WO-2005037782 (2005).
95. SANOFI-aVENTIS (Dargazanli G, Estenne-Bouhtou G, Magat P): Derivatives of N-phenyl(piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics. WO-2005037792 (2005).
96. SANOFI-SYNTHÉLABO (Dargazanli G, Estenne-Bouhtou G, Marabout B, Roger P, Sevrin M): N-[phenyl(piperidin-2-yl)methyl] benzamide derivatives, preparation thereof, and use thereof in therapy. WO-2004013101 (2004).